82 FR 15359 - Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study on Warning Statements for Cigarette Graphic Health Warnings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 82, Issue 58 (March 28, 2017)

Page Range		15359-15361
FR Document		2017-06078

The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Experimental Study on Warning Statements for Cigarette Graphic Health Warnings that is being conducted in support of the graphic label statement provision of the Family Smoking Prevention and Tobacco Control Act (the Tobacco Control Act).

Federal Register, Volume 82 Issue 58 (Tuesday, March 28, 2017)

[Federal Register Volume 82, Number 58 (Tuesday, March 28, 2017)]
[Notices]
[Pages 15359-15361]
From the Federal Register Online [www.thefederalregister.org]
[FR Doc No: 2017-06078]

[[Page 15359]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0932]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Experimental Study on Warning Statements for Cigarette
Graphic Health Warnings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on the Experimental Study on Warning
Statements for Cigarette Graphic Health Warnings that is being
conducted in support of the graphic label statement provision of the
Family Smoking Prevention and Tobacco Control Act (the Tobacco Control
Act).

DATES: Submit either electronic or written comments on the collection
of information by May 30, 2017.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-N-0932 for ``Agency Information Collection Activities,
Proposed Collection; Comment Request; Experimental Study on Warning
Statements for Cigarette Graphic Health Warnings.'' Received comments
will be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North,
10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

[[Page 15360]]

Experimental Study on Warning Statements for Cigarette Graphic Health
Warnings

OMB Control Number--0910-New

The health risks associated with the use of cigarettes can be
significant and far-reaching. In 2009, Congress enacted the Tobacco
Control Act (Pub. L. 111-31), which amends the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) to grant FDA authority to regulate the
manufacture, marketing, and distribution of tobacco products to protect
the public health and to reduce tobacco use by minors. Section 201 of
the Tobacco Control Act amends section 4 of the Federal Cigarette
Labeling and Advertising Act (FCLAA) (15 U.S.C. 1333) to require FDA to
issue ``regulations that require color graphics depicting the negative
health consequences of smoking to accompany the label statements
specified in subsection (a)(1).'' Section 202(b) of the Tobacco Control
Act further amends section 4 the FCLAA by adding that the Secretary,
through notice and comment rulemaking, may adjust the ``text of any of
the label requirements . . . if the Secretary finds that such a change
would promote greater public understanding of the risks associated with
the use of tobacco products.''
In the Federal Register of June 22, 2011 (76 FR 36628), FDA issued
a final rule entitled ``Required Warnings for Cigarette Packages and
Advertisements,'' which specified nine images to accompany the new
textual warning statements for cigarettes. Although the rule was
scheduled to become effective 15 months after it issued, a panel of the
U.S. Court of Appeals of the District of Columbia held, on August 24,
2012, that the rule in its current form violated the First Amendment.
In a letter to Congress on March 15, 2013, the Attorney General
reported FDA's intention to undertake research to support a new
rulemaking consistent with the Tobacco Control Act. Preliminary
research has been underway since 2013. Informed by the previous court
decisions on this matter, including on the First Amendment, the next
phase of the research includes the study proposed here, which is an
effort by FDA to collect data concerning revised textual warning
statements for use with new images as part of cigarette graphic health
warnings, and their potential impact on public understanding of the
risks associated with the use of cigarettes.
As currently proposed, this Experimental Study on Warning
Statements for Cigarette Graphic Health Warnings is a voluntary online
experiment conducted with consumers. The purpose of the proposed study
is to assess whether potential textual warnings statements, which have
been revised from those enumerated in section 4 of FCLAA, promote
greater public understanding of the negative health consequences of
cigarette smoking. The study will collect data from various groups of
consumers, including adolescent (under age 18) current cigarette
smokers, adolescents who are susceptible to initiation of cigarette
smoking, young adult (ages 18- to 24) current cigarette smokers, and
older adult (ages 25 and above) current cigarette smokers. The results
will inform the Agency's development of cigarette graphic health
warnings to be tested in future studies with the goal of implementing
the mandatory graphic warning label statement consistent with section
4(d) of FCLAA and the First Amendment.
Proposed Study Overview: In this study, adolescent current
cigarette smokers, adolescents who are susceptible to initiation of
cigarette smoking, young adult current cigarette smokers, and older
adult current smokers will be recruited from an Internet panel of more
than 1.2 million people and screened for inclusion into the study.
Participants who meet the inclusion criteria will be randomized into
one of 17 conditions in a between-subjects design. In each condition,
participants will be exposed to a series of nine warning statements,
presented sequentially. Participants randomized to the control
condition will view all nine of the warning statements listed in
section 4(a)(1) of FCLAA:

WARNING: Cigarettes are addictive.
WARNING: Tobacco smoke can harm your children.
WARNING: Cigarettes cause fatal lung disease.
WARNING: Cigarettes cause cancer.
WARNING: Cigarettes cause strokes and heart disease.
WARNING: Smoking during pregnancy can harm your baby.
WARNING: Smoking can kill you.
WARNING: Tobacco smoke causes fatal lung disease in
nonsmokers.
WARNING: Quitting smoking now greatly reduces serious risks to
your health.

Participants randomized to 1 of the 16 experimental conditions will
view 8 of the warning statements listed in section 4(a)(1) of FCLAA
(above) plus 1 statement that is a revised version of a statutory text
warning. The revised warning statements being tested in this proposed
study are:

WARNING: Smoking causes mouth and throat cancer.
WARNING: Smoking causes head and neck cancer.
WARNING: Smoking causes bladder cancer, which can lead to
bloody urine.
WARNING: Smoking during pregnancy causes premature birth.
WARNING: Smoking during pregnancy stunts fetal growth.
WARNING: Smoking during pregnancy causes premature birth and
low birth weight.
WARNING: Secondhand smoke causes respiratory illnesses in
children, like pneumonia.
WARNING: Smoking can cause heart disease and strokes by
clogging arteries.
WARNING: Smoking causes COPD, a lung disease that can be
fatal.
WARNING: Smoking causes serious lung diseases like emphysema
and chronic bronchitis.
WARNING: Smoking reduces blood flow, which can cause erectile
dysfunction.
WARNING: Smoking reduces blood flow to the limbs, which can
require amputation.
WARNING: Smoking raises blood sugar, which can cause type 2
diabetes.
WARNING: Smoking causes age-related macular degeneration,
which can lead to blindness.
WARNING: Smoking causes cataracts, which can lead to
blindness.

In all conditions, after viewing each statement, participants will
respond to a small number of questions about that specific statement.
Following viewing all nine statements, participants will respond to a
larger set of questions. Next, participants will view an additional
nine revised warning statements, drawn from the revised statements
listed above, and respond to an additional set of questions. Primary
study outcomes include beliefs and knowledge of the negative health
consequences of cigarette smoking. Prior to the main data collection,
two pretests, each with 50 participants, will take place to ensure
correct programming and to identify any issues with the proposed study
design and implementation.
Estimated Burden: FDA estimates the burden of this collection of
information as follows:

[[Page 15361]]

Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Portion of study Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Screening for pretest......... 762 1 762 .033 (2 minutes) 25
Pretest....................... 100 1 100 .25 (15 minutes) 25
Screening for main data 19,082 1 19,082 .033 (2 minutes) 630
collection.
Main data collection.......... 2,500 1 2,500 .25 (15 minutes) 625
------------------------------------------------ ---------------
Total..................... .............. .............. .............. ................ 1,305
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.

FDA's burden estimate is based on prior experience with research
that is similar to this proposed study. Screening potential
participants for the 2 pretests will occur with 762 respondents (487
adults and 275 adolescents) identified and recruited through the
Internet panel. This brief screening will take an average of 2 minutes
(0.033 hours) per respondent. Each of the 2 pretests will consist of 50
respondents (34 adults and 16 adolescents) conducted during a single
session and take an average of 15 minutes (0.25 hours) per respondent.
Screening potential participants for the main data collection will
occur with 19,082 respondents (11,925 adults and 7,157 adolescents)
identified and recruited through the same Internet panel as used for
the pretests. This brief screening will take an average of 2 minutes
(0.033 hours) per respondent. Recent national estimates of the numbers
of adolescent current cigarette smokers, adolescents who are
susceptible to initiation of cigarette smoking, young adult current
cigarette smokers, and older adult current cigarette smokers informed
the estimates of 13.9 percent qualification rate for adults and 11.6
percent qualification rate for adolescents. Applying these estimates
and other assumptions from previous experience conducting similar
studies to the number of adolescents and adults to be screened results
in the desired sample size for the main data collection of 2,500
participants, of which 1,667 will be adults and 833 will be
adolescents. The main data collection will occur with those 2,500
respondents during a single session. The main data collection will take
an average of 15 minutes (0.25 hours) per respondent. The total
estimated burden is 1,305 hours (25 hours + 25 hours + 630 hours + 625
hours).

Dated: March 22, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-06078 Filed 3-27-17; 8:45 am]
BILLING CODE 4164-01-P

15360 Federal Register / Vol. 82, No. 58 / Tuesday, March 28, 2017 / Notices

Experimental Study on Warning Statements for Cigarette Graphic Health statutory text warning. The revised
Statements for Cigarette Graphic Health Warnings is a voluntary online warning statements being tested in this
Warnings experiment conducted with consumers. proposed study are:
OMB Control Number—0910–New The purpose of the proposed study is to • WARNING: Smoking causes mouth
assess whether potential textual and throat cancer.
The health risks associated with the warnings statements, which have been
use of cigarettes can be significant and • WARNING: Smoking causes head and
revised from those enumerated in neck cancer.
far-reaching. In 2009, Congress enacted section 4 of FCLAA, promote greater
the Tobacco Control Act (Pub. L. 111– • WARNING: Smoking causes bladder
public understanding of the negative cancer, which can lead to bloody
31), which amends the Federal Food, health consequences of cigarette
Drug, and Cosmetic Act (the FD&C Act) urine.
smoking. The study will collect data • WARNING: Smoking during
to grant FDA authority to regulate the from various groups of consumers,
manufacture, marketing, and pregnancy causes premature birth.
including adolescent (under age 18) • WARNING: Smoking during
distribution of tobacco products to current cigarette smokers, adolescents
protect the public health and to reduce pregnancy stunts fetal growth.
who are susceptible to initiation of
tobacco use by minors. Section 201 of • WARNING: Smoking during
cigarette smoking, young adult (ages 18-
the Tobacco Control Act amends section pregnancy causes premature birth and
to 24) current cigarette smokers, and
4 of the Federal Cigarette Labeling and low birth weight.
older adult (ages 25 and above) current
Advertising Act (FCLAA) (15 U.S.C. • WARNING: Secondhand smoke
cigarette smokers. The results will
1333) to require FDA to issue causes respiratory illnesses in
inform the Agency’s development of
‘‘regulations that require color graphics children, like pneumonia.
cigarette graphic health warnings to be
depicting the negative health
tested in future studies with the goal of • WARNING: Smoking can cause heart
consequences of smoking to accompany disease and strokes by clogging
implementing the mandatory graphic
the label statements specified in arteries.
warning label statement consistent with
subsection (a)(1).’’ Section 202(b) of the
section 4(d) of FCLAA and the First • WARNING: Smoking causes COPD, a
Tobacco Control Act further amends lung disease that can be fatal.
Amendment.
section 4 the FCLAA by adding that the
Proposed Study Overview: In this • WARNING: Smoking causes serious
Secretary, through notice and comment lung diseases like emphysema and
study, adolescent current cigarette
rulemaking, may adjust the ‘‘text of any chronic bronchitis.
smokers, adolescents who are
of the label requirements . . . if the • WARNING: Smoking reduces blood
susceptible to initiation of cigarette
Secretary finds that such a change flow, which can cause erectile
smoking, young adult current cigarette
would promote greater public dysfunction.
smokers, and older adult current
understanding of the risks associated • WARNING: Smoking reduces blood
with the use of tobacco products.’’ smokers will be recruited from an
Internet panel of more than 1.2 million flow to the limbs, which can require
In the Federal Register of June 22,
people and screened for inclusion into amputation.
2011 (76 FR 36628), FDA issued a final
the study. Participants who meet the • WARNING: Smoking raises blood
rule entitled ‘‘Required Warnings for
inclusion criteria will be randomized sugar, which can cause type 2
Cigarette Packages and
Advertisements,’’ which specified nine into one of 17 conditions in a between- diabetes.
images to accompany the new textual subjects design. In each condition, • WARNING: Smoking causes age-
warning statements for cigarettes. participants will be exposed to a series related macular degeneration, which
Although the rule was scheduled to of nine warning statements, presented can lead to blindness.
become effective 15 months after it sequentially. Participants randomized to • WARNING: Smoking causes cataracts,
issued, a panel of the U.S. Court of the control condition will view all nine which can lead to blindness.
Appeals of the District of Columbia of the warning statements listed in In all conditions, after viewing each
held, on August 24, 2012, that the rule section 4(a)(1) of FCLAA: statement, participants will respond to a
in its current form violated the First • WARNING: Cigarettes are addictive. small number of questions about that
Amendment. In a letter to Congress on • WARNING: Tobacco smoke can harm specific statement. Following viewing
March 15, 2013, the Attorney General your children. all nine statements, participants will
reported FDA’s intention to undertake • WARNING: Cigarettes cause fatal lung respond to a larger set of questions.
research to support a new rulemaking disease. Next, participants will view an
consistent with the Tobacco Control • WARNING: Cigarettes cause cancer. additional nine revised warning
Act. Preliminary research has been • WARNING: Cigarettes cause strokes statements, drawn from the revised
underway since 2013. Informed by the and heart disease. statements listed above, and respond to
previous court decisions on this matter, • WARNING: Smoking during an additional set of questions. Primary
including on the First Amendment, the pregnancy can harm your baby. study outcomes include beliefs and
next phase of the research includes the • WARNING: Smoking can kill you. knowledge of the negative health
study proposed here, which is an effort • WARNING: Tobacco smoke causes consequences of cigarette smoking. Prior
by FDA to collect data concerning fatal lung disease in nonsmokers. to the main data collection, two pretests,
• WARNING: Quitting smoking now each with 50 participants, will take
revised textual warning statements for
greatly reduces serious risks to your place to ensure correct programming
use with new images as part of cigarette
health. and to identify any issues with the
sradovich on DSK3GMQ082PROD with NOTICES

graphic health warnings, and their
potential impact on public Participants randomized to 1 of the 16 proposed study design and
understanding of the risks associated experimental conditions will view 8 of implementation.
with the use of cigarettes. the warning statements listed in section Estimated Burden: FDA estimates the
As currently proposed, this 4(a)(1) of FCLAA (above) plus 1 burden of this collection of information
Experimental Study on Warning statement that is a revised version of a as follows:

VerDate Sep<11>2014 17:14 Mar 27, 2017 Jkt 241001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\28MRN1.SGM 28MRN1

Federal Register / Vol. 82, No. 58 / Tuesday, March 28, 2017 / Notices 15361

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of Total Average
Number of responses
Portion of study annual burden per Total hours
respondents per responses response
respondent

Screening for pretest .................................... 762 1 762 .033 (2 minutes) ................... 25
Pretest ........................................................... 100 1 100 .25 (15 minutes) ................... 25
Screening for main data collection ............... 19,082 1 19,082 .033 (2 minutes) ................... 630
Main data collection ...................................... 2,500 1 2,500 .25 (15 minutes) ................... 625

Total ....................................................... ........................ ........................ ........................ ............................................... 1,305
1 There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA’s burden estimate is based on Dated: March 22, 2017. ADDRESSES: The meeting will be held
prior experience with research that is Leslie Kux, online via webinar. To register to attend
similar to this proposed study. Associate Commissioner for Policy. the meeting, please visit the Healthy
Screening potential participants for the [FR Doc. 2017–06078 Filed 3–27–17; 8:45 am] People Web site at http://
2 pretests will occur with 762 BILLING CODE 4164–01–P
www.healthypeople.gov.
respondents (487 adults and 275 FOR FURTHER INFORMATION CONTACT:
adolescents) identified and recruited Emmeline Ochiai, Designated Federal
through the Internet panel. This brief DEPARTMENT OF HEALTH AND Officer, Secretary’s Advisory Committee
screening will take an average of 2 HUMAN SERVICES on National Health Promotion and
minutes (0.033 hours) per respondent. Disease Prevention Objectives for 2030,
Announcement of Meeting of the U.S. Department of Health and Human
Each of the 2 pretests will consist of 50
Secretary’s Advisory Committee on Services, Office of the Assistant
respondents (34 adults and 16
National Health Promotion and Disease Secretary for Health, Office of Disease
adolescents) conducted during a single Prevention Objectives for 2030
session and take an average of 15 Prevention and Health Promotion, 1101
minutes (0.25 hours) per respondent. Wootton Parkway, Room LL–100,
AGENCY: Office of Disease Prevention
Screening potential participants for the Rockville, MD 20852, (240) 453–8280
and Health Promotion, Office of the
main data collection will occur with (telephone), (240) 453–8281 (fax).
Assistant Secretary for Health, Office of
19,082 respondents (11,925 adults and Additional information is available on
the Secretary, Department of Health and
the Healthy People Web site at http://
7,157 adolescents) identified and Human Services.
www.healthypeople.gov.
recruited through the same Internet ACTION: Notice.
panel as used for the pretests. This brief SUPPLEMENTARY INFORMATION: The
screening will take an average of 2 names and biographies of the
SUMMARY: The U.S. Department of
minutes (0.033 hours) per respondent. Committee members are available at
Health and Human Services (HHS)
Recent national estimates of the https://www.healthypeople.gov/2020/
announces the next federal advisory
numbers of adolescent current cigarette about/history-development/healthy-
committee meeting regarding the
smokers, adolescents who are people-2030-advisory-committee.
development of national health
Purpose of Meeting: Through the
susceptible to initiation of cigarette promotion and disease prevention
Healthy People initiative, HHS leverages
smoking, young adult current cigarette objectives for 2030. This meeting will be
scientific insights and lessons from the
smokers, and older adult current held online via webinar and is open to
past decade, along with new knowledge
cigarette smokers informed the the public. The Committee will discuss
of current data, trends, and innovations,
estimates of 13.9 percent qualification the nation’s health promotion and
to develop the next iteration of national
rate for adults and 11.6 percent disease prevention objectives and will
health promotion and disease
qualification rate for adolescents. provide recommendations to improve
prevention objectives. Healthy People
Applying these estimates and other health status and reduce health risks for
provides science-based, 10-year national
assumptions from previous experience the nation by the year 2030. The
objectives for promoting health and
conducting similar studies to the Committee will advise the Secretary on
preventing disease. Since 1979, Healthy
number of adolescents and adults to be the Healthy People 2030 mission,
People has set and monitored national
vision, framework, and organizational
screened results in the desired sample health objectives that meet a broad
structure. The Committee will provide
size for the main data collection of 2,500 range of health needs, encourage
advice regarding criteria for identifying
participants, of which 1,667 will be collaboration across sectors, guide
a more focused set of measurable,
adults and 833 will be adolescents. The individuals toward making informed
nationally representative objectives. The
main data collection will occur with health decisions, and measure the
Committee’s advice must assist the
those 2,500 respondents during a single impact of our prevention and health
Secretary in reducing the number of
session. The main data collection will promotion activities. Healthy People
objectives while ensuring that the
sradovich on DSK3GMQ082PROD with NOTICES

take an average of 15 minutes (0.25 2030 health objectives will reflect
selection criteria identifies the most
hours) per respondent. The total assessments of major risks to health and
critical public health issues that are
estimated burden is 1,305 hours (25 wellness, changing public health
high-impact priorities supported by
hours + 25 hours + 630 hours + 625 priorities, and emerging technologies
current national data.
hours). related to our nation’s health
DATES: The Committee will meet on preparedness and prevention.
April 27, 2017, from 12:00 p.m. to 2:00 Public Participation at Meeting:
p.m. Eastern Time (ET). Members of the public are invited to

VerDate Sep<11>2014 17:14 Mar 27, 2017 Jkt 241001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\28MRN1.SGM 28MRN1

Document Created: 2017-03-28 00:31:59
Document Modified: 2017-03-28 00:31:59

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		Submit either electronic or written comments on the collection of information by May 30, 2017.
Contact		JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794.
FR Citation		82 FR 15359

82 FR 15359 - Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study on Warning Statements for Cigarette Graphic Health Warnings

DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug Administration

Federal Register Volume 82, Issue 58 (March 28, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration